• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善中风试验中效用加权残疾结果的可视化方法。

Improving Visualization Methods of Utility-Weighted Disability Outcomes for Stroke Trials.

作者信息

Tokunboh Ivie, Sung Eleanor Mina, Chatfield Fiona, Gaines Nathan, Nour May, Starkman Sidney, Saver Jeffrey L

机构信息

Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.

Viterbi School of Engineering, University of Southern California, Los Angeles, CA, United States.

出版信息

Front Neurol. 2022 May 13;13:875350. doi: 10.3389/fneur.2022.875350. eCollection 2022.

DOI:10.3389/fneur.2022.875350
PMID:35645952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9136165/
Abstract

BACKGROUND

The modified Rankin Scale (mRS) is the most common endpoint in acute stroke trials, but its power is limited when analyzed dichotomously and its indication of effect size is challenging to interpret when analyzed ordinally. To address these issues, the utility-weighted-mRS (UW-mRS) has been developed as a patient-centered, linear scale. However, appropriate data visualizations of UW-mRS results are needed, as current stacked bar chart displays do not convey crucial utility-weighting information.

DESIGN/METHODS: Two UW-mRS display formats were devised: (1) Utility Staircase charts, and (2) choropleth-stacked-bar-charts (CSBCs). In Utility Staircase displays, mRS segment height reflects the utility value of each mRS level. In CSBCs, mRS segment color intensity reflects the utility of each mRS level. Utility Staircase and CSBC figures were generated for 15 randomized comparisons of acute ischemic/hemorrhagic stroke therapies, including fibrinolysis, endovascular reperfusion, blood pressure moderation, and hemicraniectomy. Display accuracy in showing utility outcomes was assessed with the Tufte-lie-factor and ease-of-use assessed by formal ratings completed by a panel of 4 neurologists and emergency physicians and one nurse-coordinator.

RESULTS

The Utility Staircase and CSBC displays rapidly conveyed patient-centered valuation of trial outcome distributions not available in conventional ordinal stacked bar charts. Tufte-lie-factor (LF) scores indicated "substantial distortion" of utility-valued outcomes for 93% (14/15) of conventional stacked bar charts, vs. "no distortion" for all Utility Staircase and CSBC displays. Clinician ratings on the Figural Display Questionnaire indicated that utility information encoded in row height (Utility Staircase display) was more readily assimilated than that conveyed in segment hue intensity (CSBC), both superior to conventional stacked bar charts.

CONCLUSIONS

Utility Staircase displays are an efficient graphical format for conveying utility weighted-modified Rankin Scale primary endpoint results of acute stroke trials, and choropleth-stacked-bar-charts a good alternative. Both are more accurate in depicting quantitative, health-related quality of life results and preferred by clinician users for utility results visualization, compared with conventional stacked bar charts.

摘要

背景

改良Rankin量表(mRS)是急性中风试验中最常见的终点指标,但二分法分析时其效能有限,而序贯分析时其效应大小的指示难以解读。为解决这些问题,已开发出效用加权mRS(UW-mRS),这是一种以患者为中心的线性量表。然而,需要对UW-mRS结果进行适当的数据可视化处理,因为当前的堆积柱状图显示无法传达关键的效用加权信息。

设计/方法:设计了两种UW-mRS显示格式:(1)效用阶梯图,以及(2)分级统计图式堆积柱状图(CSBC)。在效用阶梯图显示中,mRS段的高度反映每个mRS水平的效用值。在CSBC中,mRS段的颜色强度反映每个mRS水平的效用。为15项急性缺血性/出血性中风治疗的随机对照试验生成了效用阶梯图和CSBC图,包括纤维蛋白溶解、血管内再灌注、血压调控和颅骨切除术。通过Tufte误差因子评估显示效用结果的准确性,并由4名神经科医生、急诊医生和1名护士协调员组成的小组通过正式评分评估易用性。

结果

效用阶梯图和CSBC图快速传达了以患者为中心的试验结果分布评估,这是传统序贯堆积柱状图所没有的。Tufte误差因子(LF)得分显示,93%(14/15)的传统堆积柱状图对效用值结果存在“严重失真”,而所有效用阶梯图和CSBC图均“无失真”。临床医生对图形显示问卷的评分表明,行高编码的效用信息(效用阶梯图显示)比段色调强度传达的信息(CSBC)更容易被理解,两者均优于传统堆积柱状图。

结论

效用阶梯图是传达急性中风试验效用加权改良Rankin量表主要终点结果的一种有效图形格式,分级统计图式堆积柱状图是一种很好的替代方式。与传统堆积柱状图相比,两者在描绘定量健康相关生活质量结果方面更准确,并且临床医生用户更倾向于用它们来进行效用结果可视化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/84b570a4da1c/fneur-13-875350-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/bf7a9620245a/fneur-13-875350-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/9c8922a3415f/fneur-13-875350-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/f29361e72917/fneur-13-875350-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/f73bb22a9e61/fneur-13-875350-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/84b570a4da1c/fneur-13-875350-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/bf7a9620245a/fneur-13-875350-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/9c8922a3415f/fneur-13-875350-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/f29361e72917/fneur-13-875350-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/f73bb22a9e61/fneur-13-875350-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4d6/9136165/84b570a4da1c/fneur-13-875350-g0005.jpg

相似文献

1
Improving Visualization Methods of Utility-Weighted Disability Outcomes for Stroke Trials.改善中风试验中效用加权残疾结果的可视化方法。
Front Neurol. 2022 May 13;13:875350. doi: 10.3389/fneur.2022.875350. eCollection 2022.
2
Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale.采用以患者为中心的方法,使用效用加权改良Rankin量表对急性卒中试验进行主要结局分析。
Stroke. 2015 Aug;46(8):2238-43. doi: 10.1161/STROKEAHA.114.008547. Epub 2015 Jul 2.
3
Health Utility Weighting of the Modified Rankin Scale: A Systematic Review and Meta-analysis.健康效用值对改良 Rankin 量表的加权:系统评价和荟萃分析。
JAMA Netw Open. 2020 Apr 1;3(4):e203767. doi: 10.1001/jamanetworkopen.2020.3767.
4
Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study.效用加权改良 Rankin 量表作为卒中试验的主要结局指标:一项模拟研究。
Stroke. 2018 Apr;49(4):965-971. doi: 10.1161/STROKEAHA.117.020194. Epub 2018 Mar 13.
5
Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome: Pooled Analysis of 20 000+ Patients.效用加权改良 Rankin 量表评分用于评估脑卒中结局:20000 余例患者的汇总分析。
Stroke. 2020 Aug;51(8):2411-2417. doi: 10.1161/STROKEAHA.119.028523. Epub 2020 Jul 9.
6
Suggested modification of presentation of stroke trial results.建议修改中风试验结果的呈现方式。
Int J Stroke. 2018 Oct;13(7):669-672. doi: 10.1177/1747493018778122. Epub 2018 May 15.
7
Utility-weighted modified Rankin Scale: Still too crude to be a truly patient-centric primary outcome measure?效用加权改良 Rankin 量表:作为真正以患者为中心的主要结局指标仍过于粗糙?
Int J Stroke. 2020 Apr;15(3):268-277. doi: 10.1177/1747493019830583. Epub 2019 Feb 12.
8
Adjusted horizontal stacked bar graphs ("Grotta bars") for consistent presentation of observational stroke study results.调整水平堆叠条形图("Grotta 条形图")以一致呈现观察性卒中研究结果。
Eur Stroke J. 2023 Mar;8(1):370-379. doi: 10.1177/23969873221149464. Epub 2023 Jan 13.
9
Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial.急性缺血性脑卒中患者功能结局质量的种族及其他决定因素:ENCHANTED 试验。
Stroke. 2020 Feb;51(2):588-593. doi: 10.1161/STROKEAHA.119.027639. Epub 2019 Dec 11.
10
Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm.用于卒中试验的简化改良Rankin量表的验证:来自ENCHANTED阿替普酶剂量组的经验
Int J Stroke. 2021 Feb;16(2):222-228. doi: 10.1177/1747493019897858. Epub 2020 Jan 22.

引用本文的文献

1
Long-Term Survival, Burden of Disease, and Patient-Centered Outcomes in Maximally Treated Intracerebral Hemorrhage.最大程度治疗的脑出血患者的长期生存、疾病负担及以患者为中心的结局
Ann Clin Transl Neurol. 2025 Jun;12(6):1144-1150. doi: 10.1002/acn3.70048. Epub 2025 Apr 14.
2
Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial.表皮生长因子与生长激素释放六肽联合治疗急性缺血性卒中:一项I/II期非盲、随机临床试验。
Front Neurol. 2024 Apr 4;15:1303402. doi: 10.3389/fneur.2024.1303402. eCollection 2024.

本文引用的文献

1
Choosing primary endpoints for clinical trials of health care interventions.选择医疗保健干预措施临床试验的主要终点。
Contemp Clin Trials Commun. 2019 Nov 12;16:100486. doi: 10.1016/j.conctc.2019.100486. eCollection 2019 Dec.
2
Utility-weighted modified Rankin Scale: Still too crude to be a truly patient-centric primary outcome measure?效用加权改良 Rankin 量表:作为真正以患者为中心的主要结局指标仍过于粗糙?
Int J Stroke. 2020 Apr;15(3):268-277. doi: 10.1177/1747493019830583. Epub 2019 Feb 12.
3
Letter by Berry et al Regarding Article, "Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study".
Berry等人就“卒中试验中以效用加权改良Rankin量表作为主要结局:一项模拟研究”一文所写的信。
Stroke. 2018 Dec;49(12):e337. doi: 10.1161/STROKEAHA.118.022198.
4
Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke.改良 Rankin 量表、5 年结局和卒中成本的有序和二分分析。
Neurology. 2018 Nov 20;91(21):e1951-e1960. doi: 10.1212/WNL.0000000000006554. Epub 2018 Oct 19.
5
Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials.组分终点是否相等?临床试验中复合终点实践的偏好研究。
Health Expect. 2018 Dec;21(6):1046-1055. doi: 10.1111/hex.12798. Epub 2018 Aug 14.
6
Functional Assessment for Acute Stroke Trials: Properties, Analysis, and Application.急性卒中试验的功能评估:特性、分析与应用
Front Neurol. 2018 Mar 26;9:191. doi: 10.3389/fneur.2018.00191. eCollection 2018.
7
Visual Aids for Patient, Family, and Physician Decision Making About Endovascular Thrombectomy for Acute Ischemic Stroke.可视化工具在急性缺血性脑卒中血管内取栓治疗中用于患者、家属和医生决策的辅助
Stroke. 2018 Jan;49(1):90-97. doi: 10.1161/STROKEAHA.117.018715. Epub 2017 Dec 8.
8
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.发病后 6 至 24 小时内进行取栓术治疗与缺损和梗死不匹配的脑卒中。
N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.
9
Comparison of 3-Month Stroke Disability and Quality of Life across Modified Rankin Scale Categories.不同改良Rankin量表类别下3个月卒中残疾与生活质量的比较。
Interv Neurol. 2017 Mar;6(1-2):36-41. doi: 10.1159/000452634. Epub 2016 Nov 16.
10
Guidelines for preparing color figures for everyone including the colorblind.为所有人(包括色盲患者)准备彩色图表的指南。
Pharmacol Res. 2017 May;119:240-241. doi: 10.1016/j.phrs.2017.02.005. Epub 2017 Feb 8.